Literature DB >> 12841400

Cefprozil: a review.

Sumit Bhargava1, Rakesh Lodha, S K Kabra.   

Abstract

Cefprozil is a novel third generation, broad-spectrum oral cephalosporin with activity against a spectrum of aerobic gram-negative and positive bacteria, as well as certain anaerobes. The beta-lactamase stability of cefprozil may exceed that of other oral cephalosporins for some important pathogens. Cefprozil may be a suitable alternative to several other commonly used beta-lactams and cephalosporins in the treatment of mild to moderate upper and lower respiratory tract infections including sinusitis, otitis media, pharyngitis/tonsillitis, secondary bacterial infection of acute bronchitis, and acute bacterial exacerbations of chronic bronchitis, and skin and skin structure infections in children. Available data indicate the safety of cefprozil in both pediatric and adult population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12841400     DOI: 10.1007/bf02723613

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  31 in total

1.  Phase I study of multiple-dose cefprozil and comparison with cefaclor.

Authors:  R H Barbhaiya; U A Shukla; C R Gleason; W C Shyu; R B Wilber; R R Martin; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration.

Authors:  R H Barbhaiya; U A Shukla; C R Gleason; W C Shyu; R B Wilber; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Safety and efficacy of cefprozil as part of a parenteral-oral antibiotic regimen for the treatment of suppurative skeletal infections in children.

Authors:  M Trujillo; S Ehrett; M J Hoyt-Sehnert; S Shelton; G H McCracken
Journal:  Clin Infect Dis       Date:  1996-10       Impact factor: 9.079

4.  Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model.

Authors:  D M Cappelletty; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  Phase I study of single-dose BMY-28100, a new oral cephalosporin.

Authors:  R H Barbhaiya; C R Gleason; W C Shyu; R B Wilber; R R Martin; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

6.  Cefprozil versus cefaclor in the treatment of acute and uncomplicated urinary tract infections. Cefprozil Multicenter Study Group.

Authors:  A Iravani; C A Doyle; S J Durham; R B Wilber
Journal:  Clin Ther       Date:  1992 Mar-Apr       Impact factor: 3.393

Review 7.  Pharmacology and pharmacokinetics of cefprozil.

Authors:  S L Barriere
Journal:  Clin Infect Dis       Date:  1992-06       Impact factor: 9.079

8.  Open-Label, parallel-group, multicenter, randomized study of cefprozil versus erythromycin in children with group A streptococcal pharyngitis/tonsillitis.

Authors:  I Brook; G H Aronovitz; M E Pichichero
Journal:  Clin Ther       Date:  2001-11       Impact factor: 3.393

9.  [Pharmacokinetic and clinical studies of cefprozil fine granules in children].

Authors:  K Nagano; H Maeda; T Yanagi; Y Tsuji; H Imamura; N Nakayama; M Yanagishima; S Fukuda
Journal:  Jpn J Antibiot       Date:  1992-12

Review 10.  Cefprozil, a new cephalosporin: its use in various clinical trials.

Authors:  R B Gainer
Journal:  South Med J       Date:  1995-03       Impact factor: 0.954

View more
  4 in total

Review 1.  Redefining the management of pediatric tonsillopharyngitis with cefprozil.

Authors:  Nameet Jerath; Ganesh Shetty
Journal:  Indian J Pediatr       Date:  2007-12       Impact factor: 1.967

2.  Population Pharmacokinetics of Cis-, Trans-, and Total Cefprozil in Healthy Male Koreans.

Authors:  Ji-Hun Jang; Seung-Hyun Jeong; Hea-Young Cho; Yong-Bok Lee
Journal:  Pharmaceutics       Date:  2019-10-14       Impact factor: 6.321

3.  Pharmacokinetic comparison with different assays for simultaneous determination of cis-, trans-cefprozil diastereomers in human plasma.

Authors:  Seung-Hyun Jeong; Ji-Hun Jang; Hea-Young Cho; Yong-Bok Lee
Journal:  J Pharm Anal       Date:  2020-07-05

4.  Development and Validation of an HPLC-MS/MS Method for Rapid Simultaneous Determination of Cefprozil Diastereomers in Human Plasma.

Authors:  Guodong He; Liping Mai; Xipei Wang
Journal:  Int J Anal Chem       Date:  2018-09-13       Impact factor: 1.885

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.